Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy
Mariëlle J. van Breemen(Amsterdam UMC Location University of Amsterdam), Carla E. M. Hollak(Centre For Development Studies), Frank Breunig(Universitätsklinikum Würzburg), Christoph Wanner(Universitätsklinikum Würzburg), Saskia M. Rombach(Erasmus MC), Aeilko H. Zwinderman(Amsterdam Neuroscience), Nick Dekker(Amsterdam UMC Location University of Amsterdam), Gabor E. Linthorst(Geneeskundige en Gezondheidsdienst), Ben J. Poorthuis(Amsterdam UMC Location University of Amsterdam), Johannes M. F. G. Aerts(Leiden University Medical Center)
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
September 18, 2010
Cited by 148
Related Papers
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
|Journal of Clinical Epidemiology|2005|3.3k
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
|New England Journal of Medicine|2008|1.2k
The Athlete’s Heart
|Circulation|2000|1.1k